| 124.65 -0.63 (-0.5%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 153.11 | 1-year : | 178.83 |
| Resists | First : | 131.08 | Second : | 153.11 |
| Pivot price | 126.29  |
|||
| Supports | First : | 122.46  |
Second : | 117.13 |
| MAs | MA(5) : | 125.14 |
MA(20) : | 125.61 |
| MA(100) : | 134.57 |
MA(250) : | 149.61 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 27.9 |
D(3) : | 33.5 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 177.39 | Low : | 115.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZTS ] has closed above bottom band by 20.1%. Bollinger Bands are 62.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 126.14 - 126.86 | 126.86 - 127.64 |
| Low: | 121.45 - 122.25 | 122.25 - 123.12 |
| Close: | 123.14 - 124.53 | 124.53 - 126.04 |
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Sun, 18 Jan 2026
Zoetis (ZTS) positioned within Morgan Stanley’s 2026 healthcare playbook - MSN
Fri, 16 Jan 2026
Should Fundsmith’s Support and Librela Safety Reassessment Require Action From Zoetis (ZTS) Investors? - simplywall.st
Thu, 15 Jan 2026
Zoetis Has Fallen Hard, But The Investment Case Is Still Not Obvious (NYSE:ZTS) - Seeking Alpha
Wed, 14 Jan 2026
Zoetis: Cheap Valuation And Attractive Product Launch Pipeline (NYSE:ZTS) - Seeking Alpha
Tue, 13 Jan 2026
Zoetis Inc. Stock (ZTS) Opinions on AI Diagnostics and Stock Price Dip - Quiver Quantitative
Mon, 12 Jan 2026
Zoetis (ZTS): Harnessing Growth with Minimum Rivalry - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 441 (M) |
| Shares Float | 440 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 97.7 (%) |
| Shares Short | 10,880 (K) |
| Shares Short P.Month | 8,250 (K) |
| EPS | 5.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.22 |
| Profit Margin | 28.2 % |
| Operating Margin | 39.3 % |
| Return on Assets (ttm) | 15 % |
| Return on Equity (ttm) | 49.8 % |
| Qtrly Rev. Growth | 0.5 % |
| Gross Profit (p.s.) | 15.29 |
| Sales Per Share | 21.33 |
| EBITDA (p.s.) | 9.05 |
| Qtrly Earnings Growth | 8.5 % |
| Operating Cash Flow | 2,920 (M) |
| Levered Free Cash Flow | 2,160 (M) |
| PE Ratio | 20.98 |
| PEG Ratio | 0 |
| Price to Book value | 10.19 |
| Price to Sales | 5.84 |
| Price to Cash Flow | 18.81 |
| Dividend | 0.5 |
| Forward Dividend | 0 |
| Dividend Yield | 0.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|